TrialTargeted oncology2014
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
M Di Bartolomeo et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this paperpooled itcites it